Tech Company Financing Transactions

Jaguar Gene Therapy Funding Round

Deerfield Capital, Eli Lilly and Company and Arch Venture Partners participated in a $139 million Series B capital raise for Jaguar Gene Therapy. The round was recorded on 4/14/2021.

Transaction Overview

Company Name
Jaguar Gene Therapy
Announced On
4/14/2021
Transaction Type
Venture Equity
Amount
$139,000,000
Round
Series B
Investors

Deerfield Capital (Lead Investor)

Eli Lilly and Company (Lead Investor)

Arch Venture Partners (Robert Nelsen)

Goldman Sachs

Nolan Capital

Proceeds Purpose
Jaguar will use Series B funding proceeds to continue to advance its initial pre-clinical pipeline, which utilizes the proven and well-characterized AAV9 vector to target diseases in larger patient populations with significant unmet need including galactosemia, genetic causes of autism spectrum disorder and Type 1 diabetes

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 N. Field Dr. Two Conway Park 300
Lake Forest, IL 60045
USA
Phone
Undisclosed
Website
www.jaguargenetherapy.com
Email Address
Not Recorded
Overview
Jaguar Gene Therapy, LLC is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by former AveXis leadership, Jaguar leverages a proven management team with the expertise to accelerate the development, manufacturing and commercialization of novel gene therapy treatments.
Profile
Jaguar Gene Therapy LinkedIn Company Profile
Social Media
Jaguar Gene Therapy Company Twitter Account
Company News
Jaguar Gene Therapy News
Facebook
Jaguar Gene Therapy on Facebook
YouTube
Jaguar Gene Therapy on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Joseph Nolan
  Joseph Nolan LinkedIn Profile  Joseph Nolan Twitter Account  Joseph Nolan News  Joseph Nolan on Facebook
Chief Financial Officer
Philip Donenberg
  Philip Donenberg LinkedIn Profile  Philip Donenberg Twitter Account  Philip Donenberg News  Philip Donenberg on Facebook
Chief Operating Officer
Andrew Knudten
  Andrew Knudten LinkedIn Profile  Andrew Knudten Twitter Account  Andrew Knudten News  Andrew Knudten on Facebook
VP - General Counsel
Michael Johannesen
  Michael Johannesen LinkedIn Profile  Michael Johannesen Twitter Account  Michael Johannesen News  Michael Johannesen on Facebook
VP - R & D
Sukumar Nagendran
  Sukumar Nagendran LinkedIn Profile  Sukumar Nagendran Twitter Account  Sukumar Nagendran News  Sukumar Nagendran on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/14/2021: Density venture capital transaction
Next: 4/14/2021: Theseus Pharmaceuticals venture capital transaction

 

Share this article

 

About Database of VC Transactions

We report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.